Pulmonary Therapy
Công bố khoa học tiêu biểu
* Dữ liệu chỉ mang tính chất tham khảo
Sắp xếp:
A Real-World Study of 30-Day Exacerbation Outcomes in Chronic Obstructive Pulmonary Disease (COPD) Patients Managed with Aerobika OPEP
Pulmonary Therapy - Tập 3 - Trang 163-171 - 2017
Oscillating positive expiratory pressure (OPEP) devices may reduce chronic symptoms in patients with obstructive pulmonary disease (COPD); however, no real-world studies have been performed to evaluate the benefits of these devices. The objective of this study was to measure the rate of early (30-day) moderate-to-severe exacerbations and related costs in COPD patients treated with Aerobika, an OPE...... hiện toàn bộ
Real-World Analysis of Treatment Patterns Among Hospitalized Patients with Pulmonary Arterial Hypertension
Pulmonary Therapy - Tập 7 - Trang 575-590 - 2021
Hospitalization is an important clinical factor associated with survival and rehospitalization in patients with pulmonary arterial hypertension (PAH). Thus, this study examined treatment patterns before and after hospitalization in the US-specific population. Adult PAH patients in the United States were identified using the Optum® Clinformatics® database from January 1, 2014, to June 30, 2019, and...... hiện toàn bộ
A Phase 1b Study of Vismodegib with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Pulmonary Therapy - Tập 5 - Trang 151-163 - 2019
Components of the hedgehog signaling pathway are upregulated in patients with idiopathic pulmonary fibrosis (IPF). Vismodegib, a small-molecule inhibitor of hedgehog signaling, when used in combination with currently available antifibrotic therapy, may be more efficacious than antifibrotics alone. The objective of this study was to evaluate the safety and tolerability of vismodegib plus pirfenidon...... hiện toàn bộ
Volume Management in Pulmonary Arterial Hypertension Patients: An Expert Pulmonary Hypertension Clinician Perspective
Pulmonary Therapy - Tập 4 - Trang 13-27 - 2018
Fluid volume management in patients with pulmonary arterial hypertension (PAH) is essential in preventing right ventricular failure. Volume overload may be caused by disease progression, indiscretion of dietary sodium and fluid intake, or medication side effects, and is a frequent complication in patients with PAH. Healthcare professionals (HCPs) who care for patients with PAH have a key role in m...... hiện toàn bộ
Extracorporeal Membrane Oxygenation in Acute Respiratory Failure
Pulmonary Therapy - Tập 9 - Trang 109-126 - 2023
Venovenous (VV) extracorporeal membrane oxygenation (ECMO) is a form of mechanical life support that provides full respiratory bypass in patients with severe respiratory failure as a bridge to recovery or lung transplantation. The use of ECMO for respiratory failure and capable centers offering ECMO has expanded over the years, increasing its availability. As VV-ECMO provides an artificial mechani...... hiện toàn bộ
Pulmonary Therapy 2020 Update and Podcast: Meet the Journal’s Editors-in-Chief
Pulmonary Therapy - Tập 6 - Trang 1-7 - 2020
The Editors-in-Chief of Pulmonary Therapy have prepared podcasts summarizing their current research, recent highlights from the field, and future predictions. Audio-only versions and the transcripts can be downloaded here: https://doi.org/10.6084/m9.figshare.11938863.
Validation of a New Portable Exhaled Nitric Oxide Analyzer, NIOX VERO®: Randomized Studies in Asthma
Pulmonary Therapy - Tập 3 - Trang 207-218 - 2017
Fractional exhaled nitric oxide (FeNO) is a non-invasive marker of airway inflammation, and a new portable analyzer (NIOX VERO®) is now available. Our studies aimed to assess the agreement of measurements between NIOX VERO® and a reference device (NIOX MINO®) and assess the reproducibility of NIOX VERO®. Paired FeNO readings were obtained from 112 subjects from both devices to assess agreement and...... hiện toàn bộ
Severe Asthma and Biological Therapy: When, Which, and for Whom
Pulmonary Therapy - Tập 6 - Trang 47-66 - 2019
Asthma is a heterogeneous chronic inflammatory disease of the airways that affects approximately 300 million people worldwide. About 5–10% of all asthmatics suffer from severe or uncontrolled asthma, associated with increased mortality and hospitalization, reduced quality of life, and increased health care costs. In recent years, new treatments have become available, and different asthma phenotype...... hiện toàn bộ
Pharmacological Assessment of the In Vitro Functional Selectivity of Aclidinium Bromide at M3 and M2 Muscarinic Receptors in Human Tissue
Pulmonary Therapy - Tập 1 - Trang 103-107 - 2015
M3 antagonist activity was assessed in electrically stimulated human bronchial strips; potency, onset and offset of action of aclidinium, tiotropium and ipratropium were determined. M2 antagonist activity was assessed in electrically stimulated isolated human left atria; duration of action was calculated. Aclidinium demonstrated competitive antagonism at M3 receptors with similar potency to compar...... hiện toàn bộ
Comparative Responses in Lung Function Measurements with Tiotropium in Adolescents and Adults, and Across Asthma Severities: A Post Hoc Analysis
Pulmonary Therapy - Tập 6 Số 1 - Trang 131-140 - 2020
Tổng số: 156
- 1
- 2
- 3
- 4
- 5
- 6
- 10